Skip to content
Open access

eNAMPT is a plasma biomarker of COVID-19 severity and ARDS progression linked to increased immune effector cell expression

Nov 2026 · PLoS ONE · Vol 21, pp. e0360244 - e0360244 · 0 citations · 39 references
Medicine

TL;DR

The utility of plasma eNAMPT measurements as a potential COVID-19 biomarker linked to ARDS progression and disease severity is explored and NAMPT expression in immune effector cells that correlates with COVID-19 severity and lethality is identified.

Abstract

Background The COVID-19 pandemic highlighted the critical unmet need for novel targets, biomarkers, and effective pharmacotherapies to reduce the severity/mortality of COVID pneumonia and progression to acute respiratory distress syndrome (ARDS). Extracellular NAMPT (eNAMPT) is a druggable DAMP and TLR4 ligand centrally involved in ARDS pathobiology. We explored the utility of plasma eNAMPT measurements as a potential COVID-19 biomarker linked to ARDS progression and disease severity and investigated the potential cellular source for eNAMPT release/secretion in COVID-19 subjects. Methods A plasma biomarker panel of inflammatory cytokines (IL-1β, IL-6, IL-8, IL-1RA, TNF-α), DAMPs (eNAMPT, MIF) and vascular proteins (ANG-2, PSGL-1) were evaluated in three distinct COVID-19-positive cohorts (Miami, Arizona, Tampa) (n = 277) and healthy control subjects (n = 214). Single-cell RNA sequencing (scRNA-seq) publicly available on peripheral blood mononuclear cells (PBMCs) in a subset of Tampa COVID-19 survivors (n = 18) and an autopsied COVID lung tissue database was separately analyzed for biomarker gene expression. Results Plasma biomarkers, including eNAMPT were significantly elevated in COVID-19 subjects compared to healthy controls (p < 0.0001), with IL-1RA, IL-6 and eNAMPT exhibiting the strongest diagnostic performance. Biomarker levels (all except IL-8, MIF) were higher in COVID-19 ARDS cases vs COVID-19 pneumonia (n = 154, AUC 0.71–0.79, p < 0.05) and were significantly elevated in COVID non-survivors (IL-6, IL-1RA, TNF-α, eNAMPT, ANG-2, PSGL-1) compared to survivors (p < 0.05). NAMPT gene expression was significantly upregulated in COVID-19 PBMCs compared with healthy controls, most evident within the CD14 + monocyte cluster. Relative to lung tissue from non-COVID-19 infected, NAMPT gene expression was increased in specific COVID-19 lung cell populations, including neutrophils, CD16 + monocytes, conventional dendritic cells (cDCs), fibroblasts, endothelium, and alveolar macrophages. Conclusion Our study corroborated the utility of this biomarker panel for diagnostic and severity assessment in COVID-19- associated ARDS and as a strategy for subject stratification in therapeutic trials of eNAMPT-neutralizing therapies. We further identified NAMPT expression in immune effector cells that correlates with COVID-19 severity and lethality. Together, these findings suggest NAMPT plays a key role in sustaining inflammatory activation and impairing lung regeneration in fatal COVID-19.

Read PDF

Similar papers

Open access Oct 2026

Blood biomarkers of long COVID: A cross-sectional evaluation of key cytokines and the coordination of inflammation

Introduction Long COVID is a complex pathophysiological condition linked to a heterogenous symptom profile. Dysregulation of 1) immunological and inflammatory responses, 2) endothelial/vascular function, and 3) metabolic and clotting processes have been identified; however, there remains a lack of clinically validated...

Callum Thomas, R. Ashton, E. Pretorius et al. · 0 citations
Open access Sep 2026

Association between the glucose-to-lymphocyte ratio and prognosis in COVID-19 patients

Background The coronavirus disease 2019 (COVID-19) pandemic has transitioned into an endemic stage and is no longer classified as a public health emergency of international concern. Nevertheless, the persistent emergence of novel variants with enhanced transmissibility and immune evasion potential suggests that the dis...

Cong Shi, Sheng-Ping Gong · 0 citations
Review Nov 2026

Beyond ACE2 downregulation: daphnetin as a multi-target agent for COVID-19 and rheumatic comorbidities.

The continuous emergence of SARS-CoV-2 variants (e.g., JN.1, KP.3) and the significantly elevated risk of severe COVID-19 in patients with rheumatic autoimmune diseases highlight an urgent unmet clinical need for dual-targeted therapeutics. Daphnetin (7,8-dihydroxycoumarin), a natural coumarin compound with a long hist...

Meng Chen, Nan-Nan Zhang, Qiong Wu et al. · 0 citations
Open access Oct 2026

Multipathway Biomarker Profiling of Immunothrombosis in Moderate and Severe COVID-19.

Background/Objectives: Coronavirus disease 2019 (COVID-19) is associated with immunothrombosis involving endothelial dysfunction and coagulation activation. We aimed to compare biomarkers spanning multiple immunothrombotic pathways between patients with moderate and severe COVID-19 at baseline and according to clinical...

Giovanni Bousquet, R. Lacroix, L. Pahus et al. · 0 citations
Review Open access 2026

[Insights on biological markers in post-COVID condition: a scope review].

Post-COVID condition (PCC) is characterized by the persistence of symptoms following acute SARS-CoV-2 infection. This scoping review aimed to identify and compile scientific evidence on biomarkers associated with PCC to elucidate its pathophysiology and support clinical diagnosis and management. A systematic search was...

Amanda Dos Santos de Amorim, E. Porto, Márcio Vasconcelos Oliveira · 0 citations
Open access Oct 2026

Long COVID shows IL-1 pathway dysregulation without a discrete circulating biomarker signature

Introduction Long COVID (LC) is characterized by persistent and, often, disabling symptoms, yet its biological basis remains unclear. Multiple mechanisms, including immune dysregulation, endothelial dysfunction, and persistence of SARS-CoV-2 components, have been proposed, although it is unknown whether these define di...

Francisco Muñoz-López, Marissa Flores-Santamaría, R. Santano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.